---
title: "Bide Pharmaceuticals released its 2024 annual performance, with a net profit attributable to the parent company of 117 million yuan, a year-on-year increase of 7.17%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237209318.md"
description: "According to the Zhitong Finance APP, Bide Pharmaceuticals disclosed its 2024 annual report. During the reporting period, the company achieved revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; net profit attributable to the parent company was 117 million yuan, a year-on-year increase of 7.17%; net profit excluding non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 15.09%; basic earnings per share were 1.32 yuan. The company plans to distribute a cash dividend of 9.00 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-23T14:42:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237209318.md)
  - [en](https://longbridge.com/en/news/237209318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237209318.md)
generator: "portal-rs"
---

# Bide Pharmaceuticals released its 2024 annual performance, with a net profit attributable to the parent company of 117 million yuan, a year-on-year increase of 7.17%

According to the Zhitong Finance APP, Bide (688073.SH) disclosed its annual report for 2024. During the reporting period, the company achieved revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; net profit attributable to shareholders was 117 million yuan, a year-on-year increase of 7.17%; net profit excluding non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 15.09%; basic earnings per share were 1.32 yuan. The company plans to distribute a cash dividend of 9.00 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [688073.CN](https://longbridge.com/en/quote/688073.CN.md)

## Related News & Research

- [PONS sees $2.78M Cumberland buy – Why THIS zone is crucial](https://longbridge.com/en/news/298365848.md)
- [The UK can still lead in tokenisation – but only if we move fast enough](https://longbridge.com/en/news/298258225.md)
- [When Should You Buy Balaji Amines Limited (NSE:BALAMINES)?](https://longbridge.com/en/news/298239779.md)
- [Self-Administration Proceedings Opened, Funding Secured by CEO/Founder, Transformation Completion Planned for Year-End](https://longbridge.com/en/news/298404144.md)
- [Singapore medicine group Eu Yan Sang's founding family sells bungalow for $31M](https://longbridge.com/en/news/298167922.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**